GPRC5D-CAR-T

GPRC5D-CAR-T refers to a class of chimeric antigen receptor (CAR) T-cell therapies engineered to target the G protein-coupled receptor, class C group 5 member D (GPRC5D), which is highly expressed on malignant plasma cells in multiple myeloma and has limited expression on normal tissues. These autologous cell therapies involve collecting a patient's own T cells, genetically modifying them ex vivo to express a CAR specific for GPRC5D, and reinfusing them into the patient. The modified T cells then recognize and kill multiple myeloma cells expressing GPRC5D. Several investigational products are in development or early clinical trials—including MCARH109 (Memorial Sloan Kettering), BMS-986393 (Bristol Myers Squibb), and CT071 (CARsgen Therapeutics)—with promising efficacy demonstrated in relapsed/refractory multiple myeloma patients who have failed prior lines of therapy[2][3][6]. Common adverse effects include cytokine release syndrome and neurotoxicity; unique toxicities such as dysgeusia and nail/skin changes have also been observed[7]. Development is ongoing for both relapsed/refractory multiple myeloma and plasma cell leukemia.

Other names

anti-GPRC5D CAR T-cell therapyanti-GPRC-5D CAR T-cell therapyanti-GPRC 5D CAR T-cell therapy